IP Library Granted Patent US 7,888,342
Granted Patent B2
US 7,888,342 · App. 12/644,510 · Granted Feb 15, 2011

Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,888,342
App. No.
12/644,510
Granted
Feb 15, 2011
Kind
B2
Abstract

The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.

Claims (10)

1. A method of treating fibromyalgia, the method consisting essentially of administering to a patient in need thereof an effective amount of at least one compound selected from milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof, with the proviso that the method excludes administering phenylalanine, tyrosine, or tryptophan.

2. A method of treating fibromyalgia, the method consisting essentially of administering to a patient in need thereof a daily dose of about 100 mg of active ingredient, wherein the active ingredient is at least one compound selected from milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof, with the proviso that the method excludes administering phenylalanine, tyrosine, or tryptophan.

3. The method of claim 2 , wherein the active ingredient is in tablet form.

4. The method of claim 2 , wherein the daily dose of active ingredient is divided into multiple doses per day.

5. The method of claim 4 , wherein the daily dose of active ingredient is administered as a 50 mg dose twice per day.

6. A method of treating fibromyalgia, the method consisting essentially of administering to a patient in need thereof a daily dose of about 200 mg of active ingredient, wherein the active ingredient is at least one compound selected from milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof, with the proviso that the method excludes administering phenylalanine, tyrosine, or tryptophan.

7. The method of claim 6 , wherein the active ingredient is in tablet form.

8. The method of claim 6 , wherein the daily dose of active ingredient is divided into multiple doses per day.

9. The method of claim 8 , wherein the daily dose of active ingredient is administered as a 100 mg dose twice per day.

10. The method of claim 9 , wherein the daily dose of active ingredient is administered as two 50 mg doses in the morning and two 50 mg doses in the evening.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2017
From: ROYALTY PHARMA COLLECTION TRUST
To: FOREST LABORATORIES HOLDINGS LIMITED
Reel/Frame 041668/0583 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2013
From: CYPRESS BIOSCIENCE, INC.
To: SAVELLA AIV LLC
Reel/Frame 030890/0681 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2013
From: SAVELLA AIV LLC
To: ROYALTY PHARMA COLLECTION TRUST
Reel/Frame 030890/0689 →